Tyra Biosciences reported a higher net loss for the fourth quarter and full year 2025, while simultaneously advancing its dabogratinib 3x3 clinical strategy and bolstering its leadership team. This combination of deeper losses and intensified late-stage development around dabogratinib in FGFR3-driven diseases is sharpening investor focus on the company’s precision oncology and rare disease ambitions....

The latest round of funding signifies another escalation in Amazon's commitment to the country.